Adjuvant Chemotherapy with Doxorubicin (Adriamycin) and 5–Fluorouracil in T3, NX, MO Bladder Cancer Treated with Radiotherapy

B. RICHARDS, J. R.G. BASTABLE, L. FREEDMAN, R. W. GLASHAN, GLYNIS HARRIS, D. W.W. NEWLING, M. R.G. ROBINSON, P. H. SMITH, THE YORKSHIRE UROLOGY CANCER RESEARCH GROUP

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Summary— Radical radiotherapy alone has been compared with radical radiotherapy followed by chemotherapy using doxorubicin (Adriamycin) and 5–fluorouracil in a randomised prospective study on 129 patients presenting with T3, NX, MO transitional cell carcinoma of the bladder. One hundred and ten patients were evaluable with a minimum follow‐up of 2 years. The addition of this form of chemotherapy did not appear to influence the survival rate or the proportion of patients free from tumour. It cannot be recommended for routine use in the primary treatment of infiltrating bladder cancer.

Original languageEnglish
Pages (from-to)386-391
Number of pages6
JournalBritish Journal of Urology
Volume55
Issue number4
DOIs
StatePublished - Aug 1983
Externally publishedYes

Fingerprint

Dive into the research topics of 'Adjuvant Chemotherapy with Doxorubicin (Adriamycin) and 5–Fluorouracil in T3, NX, MO Bladder Cancer Treated with Radiotherapy'. Together they form a unique fingerprint.

Cite this